Filing Details
- Accession Number:
- 0001209191-21-024891
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-04-02 20:55:31
- Reporting Period:
- 2021-03-31
- Accepted Time:
- 2021-04-02 20:55:31
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1322505 | Albireo Pharma Inc. | ALBO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1741553 | Jason Duncan | C/O Albireo Pharma Inc. 10 Post Office Square, Suite 1000 Boston MA 02109 | Chief Legal Officer And Gc | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2021-03-31 | 1,426 | $35.04 | 8,161 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-04-01 | 300 | $24.04 | 8,461 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-04-01 | 300 | $36.16 | 8,161 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2021-04-01 | 300 | $0.00 | 300 | $24.04 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 19,200 | 2029-01-21 | No | 4 | M | Direct |
Footnotes
- Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021. Includes 72 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the "ESPP") on May 31, 2019; 87 shares of common stock acquired under the ESPP on November 30, 2019; and 96 shares of common stock acquired under the ESPP on May 31, 2020.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.54 to $35.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- Represents 161 shares of common stock and 8,000 restricted stock units.
- Represents 461 shares of common stock and 8,000 restricted stock units.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.09 to $36.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- This option vested as to 25% of the shares on January 22, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on April 22, 2020 and ending on January 22, 2023.
Billionaire Hedge Funds
